1-(2-methoxyphenyl)-4-(4-(2-phthalimido)butyl)piperazine has been researched along with olomoucine in 2 studies
| Studies (1-(2-methoxyphenyl)-4-(4-(2-phthalimido)butyl)piperazine) | Trials (1-(2-methoxyphenyl)-4-(4-(2-phthalimido)butyl)piperazine) | Recent Studies (post-2010) (1-(2-methoxyphenyl)-4-(4-(2-phthalimido)butyl)piperazine) | Studies (olomoucine) | Trials (olomoucine) | Recent Studies (post-2010) (olomoucine) |
|---|---|---|---|---|---|
| 9 | 0 | 2 | 227 | 0 | 24 |
| Protein | Taxonomy | 1-(2-methoxyphenyl)-4-(4-(2-phthalimido)butyl)piperazine (IC50) | olomoucine (IC50) |
|---|---|---|---|
| Chain A, MAP KINASE P38 | Homo sapiens (human) | 27 | |
| Chain A, PROTEIN (MAP KINASE P38) | Homo sapiens (human) | 27 | |
| Chain A, PROTEIN (MAP KINASE P38) | Homo sapiens (human) | 27 | |
| Chain A, Protein (map Kinase P38) | Homo sapiens (human) | 27 | |
| Chain A, Extracellular Regulated Kinase 2 | Rattus norvegicus (Norway rat) | 27 | |
| Chain A, Extracellular Regulated Kinase 2 | Rattus norvegicus (Norway rat) | 27 | |
| G2/mitotic-specific cyclin-B2 | Homo sapiens (human) | 7 | |
| G1/S-specific cyclin-E2 | Homo sapiens (human) | 7.8 | |
| Tyrosine-protein kinase Lck | Homo sapiens (human) | 7 | |
| Cyclin-dependent kinase 1 | Homo sapiens (human) | 6.7875 | |
| Cyclin-dependent kinase 4 | Homo sapiens (human) | 7 | |
| G2/mitotic-specific cyclin-B1 | Homo sapiens (human) | 7 | |
| G2/mitotic-specific cyclin-B | Marthasterias glacialis (spiny starfish) | 5.2571 | |
| Cyclin-A2 | Homo sapiens (human) | 7.75 | |
| G1/S-specific cyclin-D1 | Homo sapiens (human) | 7 | |
| G1/S-specific cyclin-E1 | Homo sapiens (human) | 6.4436 | |
| Cyclin-dependent kinase 2 | Homo sapiens (human) | 6.5945 | |
| Mitogen-activated protein kinase 1 | Homo sapiens (human) | 7 | |
| Vascular endothelial growth factor receptor 2 | Homo sapiens (human) | 7 | |
| Cyclin-A1 | Homo sapiens (human) | 7.75 | |
| Cyclin-dependent-like kinase 5 | Homo sapiens (human) | 4.6 | |
| Cyclin-dependent kinase 5 activator 1 | Homo sapiens (human) | 5.6667 | |
| G2/mitotic-specific cyclin-B3 | Homo sapiens (human) | 7 | |
| Cyclin-dependent kinase 1 | Oryzias latipes (Japanese medaka) | 5.2571 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J | 1 |
| Austin, CP; Fidock, DA; Hayton, K; Huang, R; Inglese, J; Jiang, H; Johnson, RL; Su, XZ; Wellems, TE; Wichterman, J; Yuan, J | 1 |
2 other study(ies) available for 1-(2-methoxyphenyl)-4-(4-(2-phthalimido)butyl)piperazine and olomoucine
| Article | Year |
|---|---|
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells | 2007 |
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
Topics: Animals; Antimalarials; ATP Binding Cassette Transporter, Subfamily B, Member 1; Chromosome Mapping; Crosses, Genetic; Dihydroergotamine; Drug Design; Drug Resistance; Humans; Inhibitory Concentration 50; Mutation; Plasmodium falciparum; Quantitative Trait Loci; Transfection | 2009 |